You are currently viewing a new version of our website. To view the old version click .

Vaccines, Volume 9, Issue 5

May 2021 - 126 articles

Cover Story: Considering that SARS-CoV-2 is mainly mucosally transmitted, a therapy administered via this same route may represent a desirable approach to fight SARS-CoV-2 infection. Experience over the past few decades has clearly demonstrated that a shift from traditional needle-based to needle-free immunization can overcome a number of limitations. Therefore, in this review, we highlight the potential of using genetically modified probiotics to express SARS-CoV-2 proteins with the aim of developing candidate oral vaccines that are capable of stimulating immune responses in the gut and lung to fight COVID-19. Indeed, the crosstalk and reciprocal interaction of the gut and lung mucosa (gut–lung axis) is mediated by immune cells moving between the two districts via the bloodstream and the lymphatic ducts, leading to modulation of the immune response at both sites. View this paper.
  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (126)

  • Article
  • Open Access
1 Citations
3,195 Views
19 Pages

Use of a Novel Peptide Welding Technology Platform for the Development of B- and T-Cell Epitope-Based Vaccines

  • Francesco Nicoli,
  • Salvatore Pacifico,
  • Eleonora Gallerani,
  • Erika Marzola,
  • Valentina Albanese,
  • Valentina Finessi,
  • Sian Llewellyn-Lacey,
  • David A. Price,
  • Victor Appay and
  • Peggy Marconi
  • + 3 authors

Peptide vaccines incorporating B- and T-cell epitopes have shown promise in the context of various cancers and infections. These vaccines are relatively simple to manufacture, but more immunogenic formulations are considered a priority. We developed...

  • Perspective
  • Open Access
14 Citations
3,683 Views
11 Pages

Cancer is the second leading cause of death worldwide. Today, the critical role of the immune system in tumor control is undisputed. Checkpoint antibody immunotherapy augments existing antitumor T cell activity with durable clinical responses in many...

  • Brief Report
  • Open Access
17 Citations
4,997 Views
6 Pages

Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 Variants

  • Gabriele Anichini,
  • Chiara Terrosi,
  • Gianni Gori Savellini,
  • Claudia Gandolfo,
  • Federico Franchi and
  • Maria Grazia Cusi

Due to their increased transmissibility, three variants of high concern have emerged in the United Kingdom (also known as B.1.1.7 lineage or VOC-202012/01), South Africa (B.1.351 lineage), and Brazil (P1 lineage) with multiple substitutions in the sp...

  • Review
  • Open Access
3 Citations
3,892 Views
14 Pages

The Immune Correlates of Orthohantavirus Vaccine

  • Joon-Yong Bae,
  • Jin Il Kim,
  • Mee Sook Park,
  • Gee Eun Lee,
  • Heedo Park,
  • Ki-Joon Song and
  • Man-Seong Park

Zoonotic transmission of orthohantaviruses from rodent reservoirs to humans has been the cause of severe fatalities. Human infections are reported worldwide, but vaccines have been approved only in China and Korea. Orthohantavirus vaccine development...

  • Article
  • Open Access
8 Citations
4,491 Views
14 Pages

Balance between Protection and Pathogenic Response to Aerosol Challenge with Mycobacterium tuberculosis (Mtb) in Mice Vaccinated with TriFu64, a Fusion Consisting of Three Mtb Antigens

  • Sadaf Sulman,
  • Benjamin O. Savidge,
  • Kawther Alqaseer,
  • Mrinal K. Das,
  • Neda Nezam Abadi,
  • John E. Pearl,
  • Obolbek Turapov,
  • Galina V. Mukamolova,
  • M. Waheed Akhtar and
  • Andrea May Cooper

Tuberculosis vaccines capable of reducing disease worldwide have proven difficult to develop. BCG is effective in limiting childhood disease, but adult TB is still a major public health issue. Development of new vaccines requires identification of an...

  • Article
  • Open Access
32 Citations
7,958 Views
23 Pages

A Synthetic Peptide CTL Vaccine Targeting Nucleocapsid Confers Protection from SARS-CoV-2 Challenge in Rhesus Macaques

  • Paul E. Harris,
  • Trevor Brasel,
  • Christopher Massey,
  • C. V. Herst,
  • Scott Burkholz,
  • Peter Lloyd,
  • Tikoes Blankenberg,
  • Thomas M. Bey,
  • Richard Carback and
  • Thomas Hodge
  • + 4 authors

Background: Persistent transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has given rise to a COVID-19 pandemic. Several vaccines, conceived in 2020, that evoke protective spike antibody responses are being deployed in mass...

  • Article
  • Open Access
3 Citations
4,313 Views
16 Pages

The Costs of Introducing the Hepatitis B Birth Dose Vaccine into the National Immunization Programme in Senegal (NéoVac Study)

  • Andréa Gosset,
  • Marie Libérée Nishimwe,
  • Mamadou Yaya Diallo,
  • Lucas Deroo,
  • Aldiouma Diallo,
  • El Hadji Ba,
  • Patrizia Maria Carrieri,
  • Cheikh Sokhna,
  • Muriel Vray and
  • Yusuke Shimakawa
  • + 1 author

Some African countries are still reluctant to introduce the hepatitis B vaccine birth dose (HepB-BD) into their expanded program of immunization (EPI), partly because of logistical, economic, and cost information constraints. To assist decision-maker...

  • Article
  • Open Access
63 Citations
5,310 Views
13 Pages

The Gender Impact Assessment among Healthcare Workers in the SARS-CoV-2 Vaccination—An Analysis of Serological Response and Side Effects

  • Chiara Di Resta,
  • Davide Ferrari,
  • Marco Viganò,
  • Matteo Moro,
  • Eleonora Sabetta,
  • Massimo Minerva,
  • Alberto Ambrosio,
  • Massimo Locatelli and
  • Rossella Tomaiuolo

Healthcare professionals are considered to be at high risk of exposure and spread of SARS-CoV-2, and have therefore been considered a priority group in COVID-19 vaccination campaign strategies. However, it must be assumed that the immune response is...

of 13

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Vaccines - ISSN 2076-393X